Biotech Startups

IMBRUVICA is a prescription cancer medication (available as capsules, tablets, and oral suspension) used to treat B-cell malignancies such as CLL/SLL and Waldenström's macroglobulinemia, as well as chronic graft-versus-host disease in adults and children. It is marketed by AbbVie, and the page provides patient dosing instructions, safety warnings, and side-effect information.

1 investor

Imcyse is a clinical-stage biopharmaceutical company developing a class of specific immunotherapies for severe autoimmune diseases using its ImotopeTM platform, which produces synthetic peptides based on natural proteins to recalibrate the patient's immune system. Its pipeline targets indications including Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Neuromyelitis Optica, and Celiac Disease.

1 investor

IMEIK Technology Development develops biomedical materials based on biopolymers, bioproteins, and tissue engineering, including composite hydrogels and microsphere formulations. The company produces medical aesthetics products and is expanding its product line toward broader healthcare applications.

1 investor

An enterprise that develops and commercializes biomedical materials and biopharmaceutical products, including Class III and Class II medical devices, dermal fillers, facial threads, and proteins/peptides for medical aesthetics, dermatology, surgery, metabolic disease, and professional skincare.

1 investor

Imhotex is a biotech company focused on drug development, managed by experienced professionals in therapeutic discovery and clinical advancement. The company appears to focus on translating scientific research into novel drug candidates.

1 investor

IMIDomics develops a patient data-driven clinical discovery platform to identify drug targets for immune-mediated inflammatory diseases (IMIDs), building on 17+ years of research and data from over 17,000 IMID patients. The company combines deep immunology expertise with computational analysis to discover first-in-class therapeutics for diseases like rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.

1 investor

Immco Diagnostics is a reference laboratory in Buffalo that performs serology and biopsy testing for autoimmune diseases such as Sjögren's syndrome, rheumatoid arthritis, and lupus, along with preeclampsia risk testing and oral/maxillofacial pathology services. It serves clinicians and healthcare providers across the United States, offering proprietary biomarkers and FDA-cleared diagnostic tests.

1 investor

Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL amyloidosis and other plasma cell-driven immune diseases. Its lead candidate is being evaluated in the U.S. NEXICART-2 trial and the ex-U.S. NEXICART-1 study, with applications intended for hematology, neurology, rheumatology, and vascular indications.

1 investor

ImmPro provides top-down proteomics analytical services for biopharmaceutical development, using single-particle protein analysis to characterize proteins and proteoforms. Its offerings support gene therapy vector characterization, biomarker discovery, and disease-specific assays for areas such as neurodegeneration, oncology, and cardiometabolic disease.

1 investor

Immunara is developing a precision immunotherapy that uses patented single domain antibody (SdAb) carriers to deliver antigens or immunomodulators selectively to antigen-presenting cells, training the immune system to target specific threats. Spun out from Amsterdam UMC, the company is building a platform for targeted and personalized immunotherapy aimed at cancer and other immune-mediated diseases.

1 investor

BIIE is a research institute in Basel focused on immune engineering, supporting scientists working on synthetic immunology, computational immunology, and systems immunology. It aims to advance global child health through immune system research.

1 investor

ImmuneSpecs uses immunopeptidomics (MAPPs) technology to identify peptides presented by MHC molecules, enabling precise mapping of T cell epitopes in biotherapeutics and validation of immunotherapy targets. The company serves biopharmaceutical organizations seeking advanced antigen presentation analysis.

1 investor

Immunicom is a biotech company developing immunotherapies based on its Immunopheresis platform, a blood-filtering device that works external to the body to treat cancer and inflammatory, cardiovascular, renal, and autoimmune diseases. Its initial focus is immuno-oncology, with CE Mark approval in Europe for advanced triple-negative breast cancer and multiple ongoing clinical trials.

1 investor

Immunique is a science-based biotech company developing cell therapies that restore balance in the immune system to treat disease and support long-term patient recovery. Its research focuses on immune cell function and is aimed at extending healthy lifespan through clinical- and data-driven treatment strategies.

1 investor

ImmunoBiochem develops degrader-antibody conjugate (DAC) therapeutics that combine antibody targeting with targeted protein degradation for precision immunology and inflammation. Its pipeline targets autoimmune and inflammatory disorders, using computational tools and disease models to design non-cytotoxic payloads.

1 investor

ImmunoBlue develops nanoimmunotherapies for cancer treatment by combining nanotechnology and immunotherapy. It operates in the biotech and therapeutics space.

1 investor

Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.

1 investor

Yicura is a clinical-stage biotechnology company developing DNA medicines and antibody immunotherapies for cancer, inflammatory, and infectious diseases using proprietary vaccine and antibody platforms.

1 investor

ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment. The company was spun off from Singapore's A*STAR research institute and serves the immunotherapy and oncology sectors.

1 investor

ImmunoStep produces monoclonal antibodies for research use, including recombinant antibodies that target specific T-cell receptors for flow cytometry applications in immunology research.

1 investor

Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.

1 investor

ImmunoWake develops immunocytokine therapeutics that use targeted precision delivery to harness the anti-tumor potential of cytokines while reducing their systemic toxicity. The company is building a pipeline of immunocytokine drugs to treat cancer and autoimmune diseases.

1 investor

Immutep is a late clinical-stage biotechnology company developing immunotherapies targeting the LAG-3 (Lymphocyte Activation Gene-3) immune molecule to treat cancer and autoimmune diseases. Its product portfolio uses LAG-3 to either stimulate the immune response against cancer or modulate it to address autoimmune conditions.

1 investor

Impact Medical Innovations develops diagnostic technologies for detecting ovarian and prostate cancer, with a focus on creating affordable, accessible point-of-care solutions to address global healthcare gaps.

1 investor